Oncology

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be used in addition to current HIV treatment. In trials, 81% of participants on the regimen achieved HIV RNA suppression, meaning their HIV levels were low enough to be considered undetectable after 6 months, with 83% showing continued viral load suppression after a year. The drug was rejected by the US regulator earlier this year, just a few months after t...

Explore More...

fake-news-misinformation-in-the-healthcare-medical-health-sector

Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization

Horizon, Viela Deal; Concert Schizophrenia Drug Flop; Gilead, Gritstone Deal

Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

recent-pharma-happenings-for-nirogy-iterum-tscan

Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials

latest-pharma-biotech-news-updates-for-eli-lilly-vera-therapeutics-gritstone

Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.

Biohaven's Troriluzole; Daiichi/ AZ's Enhertu; Fujifilm Manufacturing Units

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

recent-pharma-happenings-for-senseonics-alkermes-hologic

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

recent-pharma-biotech-healthcare-news-and-updates-for-nih-roche-regeneron-gsk

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Atsena raises $55M; Neuron23’s strategy for CNS disorders; and more

Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders

Hepatitis B and C Treatment and Upcoming Therapies

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

recent-pharma-biotech-news-updates-for-astrazeneca-uniqure-csl

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH therapy

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

recent-pharma-biotech-news-and-updates-for-zimmer-bayer-ovid-merck-janssen-roche

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization

Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone

Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials

Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.

Biohaven’s Troriluzole Failure; Daiichi/ AZ’s Enhertu; Fujifilm & Manufacturing Spree; J&J’s Darzalex Faspro

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Medical Tourism: Road to Affordable and Quality Medical Care

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

More Views & Analysis

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Subscribe to our Updates

Daily

Weekly

Monthly